Navigation Links
Oramed Pharmaceuticals Reports Last Patient Out in Phase IIa Trial for ORMD-0801 in Type 1 Diabetes
Date:8/7/2014

ions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801), having completed separate Phase IIa clinical trials, and anticipating the initiation of separate Phase IIb clinical trials, in patients with both type 1 and type 2 diabetes under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral GLP-1 analog capsule (ORMD-0901).  For more information, the content of which is not part of this press release, please visit: http://www.oramed.com

Forward-looking statements:  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials, including the expected timing thereof, timing for reporting data from our clinical trials, the anticipated safety of ORMD-0801 and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks a
'/>"/>

SOURCE Oramed Pharmaceuticals Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Oramed Pharmaceuticals Granted 2nd Patent in New Zealand; 3rd Patent for Core Technology on Oral Delivery of Proteins
2. Oramed Pharmaceuticals Announces Reverse Stock Split
3. Bioassociate Announces Initiation of Coverage on Oramed Pharmaceuticals, Inc.
4. Oramed Pharmaceuticals Moves Forward with Investigational New Drug Application for Oral Insulin
5. Oramed CEO to be Panelist at BIO International Convention Breakout Session on Israel Becoming Biotech Leader
6. Oramed Submits Pre-IND Package to FDA for ORMD-0901 (oral exenatide), an Oral GLP-1 Analog for the Treatment of Type 2 Diabetes
7. Oramed to Participate in Barclays Israel Biotech Corporate Day in Zurich on September 30, 2013
8. Keryx Biopharmaceuticals, Inc. Announces Upcoming Poster Presentations of Zerenex™ (Ferric Citrate) at the Upcoming American Society of Nephrology Kidney Week 2011 Annual Meeting
9. Convergence Pharmaceuticals Initiates Phase I Multiple Ascending Dose Study for CNV2197944
10. TetraLogic Pharmaceuticals Announces Initiation of a Phase 1/2 Clinical Trial of TL32711 in Patients with Acute Myelogenous Leukemia (AML)
11. Questcor Pharmaceuticals to Present at the Oppenheimer Healthcare Conference on December 13, 2011
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
(Date:7/30/2015)... customers across the globe, ISN improves the efficiency and effectiveness of contractor management systems. ... and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In More Than 80 Countries ... Headquartered in Dallas, TX , ISN has additional offices in ...
(Date:7/30/2015)... July 30, 2015 HIGHLIGHTS:Q2 2015 ... 2014) , Reported sales were $697 million compared ... Sales grew organically by 8%, and changes in foreign ... increased sales by 1%. , By business unit, ... Applied and 11% in SAFC Commercial. , Reported ...
(Date:7/30/2015)... ... July 30, 2015 , ... As part of its 2015 growth plan and as ... technical service business units, Whitehouse Laboratories is pleased to announce that it has ... the Container Center of Excellence and will be strictly dedicated to basic USP 51, USP ...
Breaking Biology Technology:Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 2Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 3Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 4Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 5Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 6Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 7Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 8Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 9Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 10Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 11Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 12Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 13Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 14Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 15Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 16Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 17Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 18Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 19Sigma-Aldrich (NASDAQ - SIAL) Reports Q2 2015 Sales Of $697 Million And Adjusted Diluted EPS Of $1.01 20Whitehouse Labs Formally Announces Plans to Open a Microbiological Laboratory 2
... MOUNTAIN VIEW, Calif., Oct. 16 Based on ... in healthcare, Frost & Sullivan recognizes Agile Therapeutics, ... & Biotechnology Healthcare Innovation of the Year Award ... lead product, AG200-15 with SKINFUSION(TM), offers great potential ...
... 16 MGM Innova, LLC (MGM Innova) and MACTEC ... alliance in carbon management services. Marco G. Monroy, President ... of MACTEC Engineering and Consulting, Inc., made the joint ... become the leading provider of integrated solutions across the ...
... AUSTIN, TexasResearchers at The University of Texas at Austin have ... world,s smallest test tube, measuring a thousandth the diameter of ... small that a high-power electron microscope was required to see ... the test tube was stuffed with a thread-like crystal (a ...
Cached Biology Technology:Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 2Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 3Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 4Frost & Sullivan Recognizes Agile Therapeutics for Its Innovative Weekly Low-Dose Contraceptive Patch 5MACTEC and MGM Innova Announce Strategic Alliance in Carbon Management Services 2Tiny test tube experiment shows reaction of melting materials at the nano scale 2
(Date:7/27/2015)... 27, 2015   Zynx Health ™, the ... improvement solutions, today announced that its ZynxCarebook ... on Android smartphones and tablets. With this expansion, ... can use ZynxCarebook to securely exchange messages and ... care transitions to other care settings, and improve ...
(Date:7/21/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ... focused on the growing mobile commerce market and ... it has filed provisional patent 62/192218 for ... This invention highlights next generation payment technology ... but also the user using unique personal identifiers ...
(Date:7/13/2015)... , Jul. 13, 2015 NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... provisional patent 62/188684 for BEHAVIORAL-DIRECTED AUTHENTIATION ... new convenient and secure method to make payments.  ... payment methods, introduced with its groundbreaking voice-direct payment ...
Breaking Biology News(10 mins):Zynx Health Adds Android Device Support to ZynxCarebook Solution 2Zynx Health Adds Android Device Support to ZynxCarebook Solution 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4NXT-ID Patents Behavior-Directed Payments 2NXT-ID Patents Behavior-Directed Payments 3NXT-ID Patents Behavior-Directed Payments 4
... of the University of Granada has found out ... the olive skin wax extracted from alpeorujo (crushed olive pulp), ... apoptosis in carcinogenic processes., Maslinic acid is a protease inhibitor ... growth. It is useful for cancer treatment, as it allows ...
... cigarette after a Valentines Day snuggle can prematurely end a ... in a gene significantly increases a smokers risk of an ... to 70 percent of the population has a gene defect ... recent published study, heavy smokers with this common gene variant ...
... Critically ill patients who need a ventilator to ... infection, however, is exceedingly difficult to diagnose because a ... masks pneumonia,s symptoms a reality that can delay ... at Washington University School of Medicine in St. Louis ...
Cached Biology News:A compound extracted from olives inhibits cancer cells growth and prevents their appearance 2Cigarette after Valentine snuggle deadlier for some 2Cigarette after Valentine snuggle deadlier for some 3Gene chips used to distinguish ventilator-associated pneumonia from underlying critical illness 2Gene chips used to distinguish ventilator-associated pneumonia from underlying critical illness 3Gene chips used to distinguish ventilator-associated pneumonia from underlying critical illness 4
... Ac-DEVD-CHO is an ... activity. The concentration of ... caspase activity must be ... system. Ten micromolar inhibitor ...
TUNEL Apoptosis Detection Kit...
Human RELT/TNFRSF19L Affinity Purified Polyclonal Ab...
homeo box D3, mRNA...
Biology Products: